Meropenem Versus Meropenem Plus Glycopeptide in Patients With Febrile Neutropenia After Allogenic Blood Stem Cell Transplantation

• Status: Completed
• Trial end date: 2009-04-01
• Target enrollment: 0
• Participant gender: All

Summary

Observational study to compare the treatment in neutropenic patients after allogenic blood stem cell transplantation, with meropenem or meropenem plus glycopeptide.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: PETHEMA Foundation
• Treatments: Meropenem; Teicoplanin; Thienamycins; Vancomycin

Criteria

Inclusion Criteria:

• Age > 18 years

• Patients submitted to allogenic transplant

• Neutropenia: neutrophils account < 500/mm3 or neutrophils account < 1000/mm3 with prevision to decrease until 500/mm3 at the next 24-48 h

• Signs and symptoms to infection

• Fever: Temperature> 38,3 ºC registered one time, or 38 ºC en two times separated 60 minutes in a period of 12 h.

Exclusion Criteria:

• Medical history of meropenem or glycopeptides hypersensitivity

• Renal failure or creatinine in serum > 2,25 mg/dl or creatinine clearance < 40 ml

• Liver insufficiency

• Childbearing potential or breast feeding period

• Contraindications to meropenem, vancomycin or teicoplanin